期刊文献+

利妥昔单抗诱导的血清病一例并文献复习

Rituximab-induced serum sickness:report of one case and review of literature
原文传递
导出
摘要 目的提高对利妥昔单抗诱导的血清病的认识。方法回顾性分析2018年7月川北医学院附属医院1例利妥昔单抗诱导的血清病患者的临床资料,并复习相关文献。结果该患者明确诊断为弥漫大B细胞淋巴瘤,给予4个疗程含利妥昔单抗的方案化疗后,出现关节炎、皮疹等表现,再次使用利妥昔单抗后,关节炎进一步加重,最终诊断为利妥昔单抗诱导的血清病。给予激素治疗,并停用利妥昔单抗,未再出现关节症状。结论对于有利妥昔单抗输注史,出现关节炎、皮疹、发热等临床表现的患者,需警惕利妥昔单抗诱导的血清病,该病对激素反应佳,但再次使用利妥昔单抗时应谨慎。
作者 林晓静 邹兴立 倪勋 魏锦 Lin Xiaojing;Zou Xingli;Ni Xun;Wei Jin(Department of Hematology,the Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China)
出处 《白血病.淋巴瘤》 CAS 2020年第2期126-128,共3页 Journal of Leukemia & Lymphoma
基金 南充市市校科技战略合作项目(18SXHZ0136)。
作者简介 通信作者:林晓静,Email:23105171@qq.com。
  • 相关文献

参考文献2

二级参考文献21

  • 1Pfreundschuh M,Trumper L,Osterborg A,et al.CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group[J].Lancet Oncol,2006,7:379-391.
  • 2Tony HP,Burmester G,Schulze-Koops H,et al.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases:experience from a national registry (GRAID)[J].Arthritis Res Ther,2011,13:R75.
  • 3Patel VL,Mahevas M,Lee SY,et al.Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia[J].Blood,2012,119:5989-5995.
  • 4Kimby E.Tolerability and safety of rituximab (MabThera)[J].Cancer Treat Rev,2005,3 1:456-473.
  • 5Yang B,Lu XC,Yu RL,et al.Diagnosis and treatment of rituximab-induced acute tumor lysis syndrome in patients with diffuse large B-cell lymphoma[J].Am J Med Sci,2012,343:337-341.
  • 6Kasi PM,Tawbi HA,Oddis CV,et al.Clinical review:serious adverse events associated with the use of rituximab-a critical care perspective[J].Crit Care,2012,16:231.
  • 7Liote H,Liote F,Seroussi B,et al.Rituximab-induced lung disease:a systematic literature review[J].Eur Respir J,2010,35:681-687.
  • 8Hadjinicolaou AV,Nisar MK,Parfrey H,et al.Non-infectious pulmonary toxicity of rituximab:a systematic review[J].Rheumatology,2012,51:653-662.
  • 9Wu Y,Jia Y,Xu J,et al.Fatal interstitial lung disease induced by rituximab-containing chemotherapy,treatment with TNF-alpha antagonist and cytokine profiling:a case-report and review of the literature[J].J Clin Pharm Ther,2013,38:249-253.
  • 10Herishanu Y,Polliack A,Leider-Trejo L,et al.Fatal interstitial pneumonitis related to rituximab-containing regimen[J].Clin Lymphoma Myeloma,2006,6:407-409.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部